Alpharmagen, Inc. Report issue

For profit Phase 2
Founded: South San Francisco CA United States (2013)
Status: Defunct (2018)

Organization Overview

First Clinical Trial
2014
NCT02331433
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

apn-1125 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Schizophrenia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1